Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
96 hedge funds and large institutions have $1.66B invested in Verve Therapeutics in 2021 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 10 closing their positions.
230% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 10
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
32% more funds holding
Funds holding: 73 → 96 (+23)
13.07% more ownership
Funds ownership: 80.68% → 93.75% (+13%)
8% less capital invested
Capital invested by funds: $1.81B → $1.66B (-$151M)
33% less call options, than puts
Call options by funds: $501K | Put options by funds: $745K
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$64M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$63.8M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$16.8M |
| 4 |
BlackRock
New York
|
+$12.6M |
| 5 |
Rafferty Asset Management
New York
|
+$6.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$27.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$23.9M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$6.74M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.01M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.32M |
VERV Hedge Fund Activity: Q4 2021 in Review
96 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q4 2021, worth a combined $1.66B — down 8.3% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new VERV positions and 10 closed out — a net gain of 23 holders — while 32 added to existing stakes and 18 trimmed.
The largest buyer was State Street, adding an estimated $64M. The largest seller was Wellington Management Group, cutting an estimated $27.5M.
- 96 institutional investors held Verve Therapeutics (VERV) as of Q4 2021, up from 73 in Q3 2021.
- Funds reported $1.66B of Verve Therapeutics stock for Q4 2021, down 8.3% quarter-over-quarter.
- 33 funds opened new Verve Therapeutics positions in Q4 2021 and 10 closed out, a net change of +23 holders.
- The largest Verve Therapeutics buyer in Q4 2021 was State Street, an estimated $64M added.
- The largest Verve Therapeutics seller in Q4 2021 was Wellington Management Group, an estimated $27.5M sold.
Based on aggregated 13F filings for Q4 2021.